SCHEMBL25310348

SCHEMBL25310348

COC(=O)CCc1cc(Cl)c(OCCOCCCOCc2ccccc2)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
TTR P02766 1/20 0.41
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.39
ALOX5 P09917 1/20 0.38
REN P00797 1/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 2/20 0.38
NPY1R P25929 1/20 0.38
NPY2R P49146 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25310708 0.98 MEN1 (0.41) MEN1KMT2ATHRATHRBTTR
SCHEMBL25312465 0.98 THRA (0.43) MEN1KMT2ATHRATHRBLMNA
SCHEMBL25312620 0.91 THRA (0.41) MEN1KMT2ATHRATHRBLMNA
SCHEMBL25314144 0.85 MAPT (0.52) MAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL25310823 0.84 MAPT (0.39) THRATHRBTTRMAPTREN
SCHEMBL25310570 0.84 MAPT (0.40) MEN1KMT2ATHRATHRBTTR
SCHEMBL26740605 0.84 THRA (0.44) KMT2ATHRATHRBMAPTREN
SCHEMBL25312138 0.83 TTR (0.38) MEN1KMT2ATHRATHRBTTR
SCHEMBL25310293 0.83 MAPT (0.40) MEN1KMT2ATHRATHRBTTR
SCHEMBL26739987 0.83 THRB (0.49) THRATHRBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 US disclosed
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 US disclosed
EP-4214189-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL Business Ltd (GB) 2023-07-26 EP disclosed
WO-2022058733-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS PLC (GB) 2022-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS TTR, C1R, APOB MEN1 2876/4885KMT2A 4615/4885THRA 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.